Evidence map›Paper›PMID 33634350›Full record

Trial reportAnnals of hematology2021

Dynamic evaluation of the prognostic value of

Pengpeng Xu, Rui Guo, Jianhua You, Shu Cheng, Jian Li, Huijuan Zhong, Chenwei Sun, Haoping Xu, Hengye Huang, Biao Li and 1 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The role ofFrontiers in oncology · 2025
    Article
  5. Frontiers in oncology · 2025
    Article
  6. Appropriate timing to perform an interimAnnals of hematology · 2024
    Article
  7. Article
  8. Article
  9. American journal of nuclear medicine and molecular imaging · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Pengpeng Xu *Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Rui Guo *Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Jianhua You *Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Shu ChengShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Jian LiClinical Research Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Huijuan ZhongShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Chenwei SunDepartment of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Haoping XuDepartment of Radiation, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Hengye HuangSchool of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Biao LiDepartment of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. lb10363@rjh.com.cn.ORCID http://orcid.org/0000-0002-0493-2062
Weili ZhaoShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. zhao.weili@yahoo.com.
Shanghai Jiao Tong University · CN

Funding

Shanghai Municipal Key Clinical Specialty shslczdzk03403Three-year planning of the Shanghai Shen-Kang Promoting Hospital's Clinical Skills and Innovative Ability Project 16CR3110B
6 · The paper itself

Abstract

Extranodal natural killer/T-cell lymphoma, nasal-type (ENKTL) is a type of rare and distinct entity of non-Hodgkin lymphoma with poor prognosis. It is important to evaluate the early treatment response accurately to decide further treatment strategy.

Indexed as

Nasal CavityPositron Emission Tomography Computed TomographyAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsAsparaginaseDexamethasoneEtoposideFemaleFluorine RadioisotopesFluorodeoxyglucose F18Follow-Up StudiesHumansKaplan-Meier EstimateLymphoma, Extranodal NK-T-CellAsparaginaseDexamethasoneEtoposideFluorine-18Fluorine RadioisotopesFluorodeoxyglucose F18MethotrexatepegaspargasePolyethylene GlycolsRadiopharmaceuticals18F-FDGExtranodal natural killer/T-cell lymphomaPET/CTPrognosis

Identifiers

PMID33634350
OpenAlexW3130023606

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.